← All trials
NCT04320277
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2020
- Primary completion
- Apr 30, 2020
- Completion date
- Apr 30, 2020
- First posted
- Mar 24, 2020
- Last posted
- Mar 24, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Azienda USL 4 PratoLead sponsor
- Azienda USL 4 PratoReponsible party - principal investigator
- Azienda USL 4 PratoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.